Protagonist Therapeutics Analyst Starts Coverage Optimistically; Check Out the Top 3 Initiations for Friday
Analyst Ratings Updates: Top Wall Street analysts have revised their outlooks on several companies, including Theravance Biopharma, Protagonist Therapeutics, and StandardAero, with new ratings and price targets announced.
Specific Stock Ratings: B. Riley Securities rated Theravance Biopharma with a Buy and a target of $28; Protagonist Therapeutics received an Outperform rating with a target of $73; and Barclays rated StandardAero as Overweight with a target of $32.
Trade with 70% Backtested Accuracy
Analyst Views on SARO
About SARO
About the author

- Significant Revenue Growth: StandardAero reported revenue of $1.63 billion in Q1 2026, reflecting double-digit growth across its three major markets, indicating strong commercial demand and market adaptability.
- Adjusted EBITDA Increase: Adjusted EBITDA rose to $203 million, a 14% increase year-over-year, demonstrating the company's success in achieving higher margins through improved productivity and optimized product mix.
- Acquisition of Unified Turbines: This acquisition enhances the company's repair capabilities on critical engines, expected to accelerate component repair turnaround times, thereby improving MRO customer satisfaction and competitive positioning.
- Upward Revision of Full-Year Outlook: The company raised its full-year revenue guidance to a range of $6.325 billion to $6.45 billion and adjusted EPS guidance to $1.40 to $1.50, reflecting management's confidence in future market demand.
- Q1 Performance: StandardAero reported a Q1 non-GAAP EPS of $0.33 and revenue of $1.63 billion, demonstrating strong performance in the aerospace services market and solidifying its position in the industry.
- 2026 Revenue Outlook: The company raised its full-year 2026 revenue guidance to $6.325 billion to $6.450 billion, reflecting an optimistic outlook on future market demand, which is expected to drive overall business growth.
- Engine Services Growth: The revenue forecast for the Engine Services segment has been increased to $5.550 billion to $5.650 billion, indicating strong market potential driven by the demand for maintenance of aging fleets, allowing the company to capitalize on industry trends.
- Adjusted EPS Increase: The adjusted earnings per share guidance has been raised to $1.40 to $1.50, showcasing enhanced profitability and further attracting investor interest in the company's long-term growth potential.
- Company Overview: Standard Aero, Inc. reported a pre-tax profit of $104.947 million for the first quarter.
- Financial Performance: The financial results indicate a strong performance in the company's operations during the specified period.
Company Overview: Standard Aero, Inc. is a prominent player in the aerospace industry, focusing on maintenance, repair, and overhaul (MRO) services for aircraft engines and components.
Financial Performance: The company reported earnings per share (EPS) of $0.24 for the first quarter, indicating a positive financial outlook.
Market Position: Standard Aero continues to strengthen its market position through strategic investments and partnerships within the aerospace sector.
Future Prospects: The company is poised for growth, leveraging advancements in technology and increasing demand for MRO services in the aviation industry.
- Company Overview: Standard Aero, Inc. reported a net income of USD 79.93 million for the first quarter.
- Financial Performance: The financial results indicate a strong performance in the company's operations during the specified period.
- Company Overview: Standard Aero, Inc. reported an operating income of USD 143.098 million for the first quarter.
- Financial Performance: The reported income reflects the company's financial health and operational efficiency during the specified period.







